Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients

Giuseppe Derosa, Pietro Putignano, Antonio C. Bossi, Aldo Bonaventura, Fabrizio Querci, Ivano G. Franzetti, Barbara Guazzini, Gianpaolo Testori, Elena Fogari, Pamela Maffioli

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin. One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study. Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1 mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2 mg three times a day for 12 months in a randomized, single-blind, controlled study. We evaluated at the baseline and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA 1c, glycemic control, fasting plasma insulin, homeostasis model assessment insulin resistance index (HOMA-IR) index, adiponectin, tumor necrosis factor-α, and high sensitivity-C reactive protein. Both treatments gave a similar improvement of glycemic control, without any differences between the two groups. Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein. Furthermore, the values obtained with exenatide were significantly better than the values recorded with glimepiride. We can conclude that exenatide was better than glimepiride in improving insulin resistance and inflammatory state. Furthermore, adiponectin increase, and tumor necrosis factor-α reduction seem to be related to weight loss obtained with exenatide.

Original languageEnglish
Pages (from-to)251-256
Number of pages6
JournalEuropean Journal of Pharmacology
Volume666
Issue number1-3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

glimepiride
Metformin
Insulin Resistance
Adiponectin
Tumor Necrosis Factor-alpha
C-Reactive Protein
Fasting
Body Mass Index
Homeostasis
Body Weight
Insulin
Single-Blind Method
exenatide
Type 2 Diabetes Mellitus
Weight Loss

Keywords

  • Adiponectin
  • Exenatide
  • Glimepiride
  • Insulin resistance
  • Tumor necrosis factor-a

ASJC Scopus subject areas

  • Pharmacology

Cite this

Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. / Derosa, Giuseppe; Putignano, Pietro; Bossi, Antonio C.; Bonaventura, Aldo; Querci, Fabrizio; Franzetti, Ivano G.; Guazzini, Barbara; Testori, Gianpaolo; Fogari, Elena; Maffioli, Pamela.

In: European Journal of Pharmacology, Vol. 666, No. 1-3, 09.2011, p. 251-256.

Research output: Contribution to journalArticle

Derosa, G, Putignano, P, Bossi, AC, Bonaventura, A, Querci, F, Franzetti, IG, Guazzini, B, Testori, G, Fogari, E & Maffioli, P 2011, 'Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients', European Journal of Pharmacology, vol. 666, no. 1-3, pp. 251-256. https://doi.org/10.1016/j.ejphar.2011.05.051
Derosa, Giuseppe ; Putignano, Pietro ; Bossi, Antonio C. ; Bonaventura, Aldo ; Querci, Fabrizio ; Franzetti, Ivano G. ; Guazzini, Barbara ; Testori, Gianpaolo ; Fogari, Elena ; Maffioli, Pamela. / Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. In: European Journal of Pharmacology. 2011 ; Vol. 666, No. 1-3. pp. 251-256.
@article{9e25d5c13b9e4d7e8f5d1b46e1bb0f1c,
title = "Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients",
abstract = "The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin. One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study. Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1 mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2 mg three times a day for 12 months in a randomized, single-blind, controlled study. We evaluated at the baseline and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA 1c, glycemic control, fasting plasma insulin, homeostasis model assessment insulin resistance index (HOMA-IR) index, adiponectin, tumor necrosis factor-α, and high sensitivity-C reactive protein. Both treatments gave a similar improvement of glycemic control, without any differences between the two groups. Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein. Furthermore, the values obtained with exenatide were significantly better than the values recorded with glimepiride. We can conclude that exenatide was better than glimepiride in improving insulin resistance and inflammatory state. Furthermore, adiponectin increase, and tumor necrosis factor-α reduction seem to be related to weight loss obtained with exenatide.",
keywords = "Adiponectin, Exenatide, Glimepiride, Insulin resistance, Tumor necrosis factor-a",
author = "Giuseppe Derosa and Pietro Putignano and Bossi, {Antonio C.} and Aldo Bonaventura and Fabrizio Querci and Franzetti, {Ivano G.} and Barbara Guazzini and Gianpaolo Testori and Elena Fogari and Pamela Maffioli",
year = "2011",
month = "9",
doi = "10.1016/j.ejphar.2011.05.051",
language = "English",
volume = "666",
pages = "251--256",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients

AU - Derosa, Giuseppe

AU - Putignano, Pietro

AU - Bossi, Antonio C.

AU - Bonaventura, Aldo

AU - Querci, Fabrizio

AU - Franzetti, Ivano G.

AU - Guazzini, Barbara

AU - Testori, Gianpaolo

AU - Fogari, Elena

AU - Maffioli, Pamela

PY - 2011/9

Y1 - 2011/9

N2 - The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin. One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study. Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1 mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2 mg three times a day for 12 months in a randomized, single-blind, controlled study. We evaluated at the baseline and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA 1c, glycemic control, fasting plasma insulin, homeostasis model assessment insulin resistance index (HOMA-IR) index, adiponectin, tumor necrosis factor-α, and high sensitivity-C reactive protein. Both treatments gave a similar improvement of glycemic control, without any differences between the two groups. Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein. Furthermore, the values obtained with exenatide were significantly better than the values recorded with glimepiride. We can conclude that exenatide was better than glimepiride in improving insulin resistance and inflammatory state. Furthermore, adiponectin increase, and tumor necrosis factor-α reduction seem to be related to weight loss obtained with exenatide.

AB - The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin. One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study. Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1 mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2 mg three times a day for 12 months in a randomized, single-blind, controlled study. We evaluated at the baseline and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA 1c, glycemic control, fasting plasma insulin, homeostasis model assessment insulin resistance index (HOMA-IR) index, adiponectin, tumor necrosis factor-α, and high sensitivity-C reactive protein. Both treatments gave a similar improvement of glycemic control, without any differences between the two groups. Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein. Furthermore, the values obtained with exenatide were significantly better than the values recorded with glimepiride. We can conclude that exenatide was better than glimepiride in improving insulin resistance and inflammatory state. Furthermore, adiponectin increase, and tumor necrosis factor-α reduction seem to be related to weight loss obtained with exenatide.

KW - Adiponectin

KW - Exenatide

KW - Glimepiride

KW - Insulin resistance

KW - Tumor necrosis factor-a

UR - http://www.scopus.com/inward/record.url?scp=79959975635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959975635&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2011.05.051

DO - 10.1016/j.ejphar.2011.05.051

M3 - Article

VL - 666

SP - 251

EP - 256

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -